Compare Travere Therapeutics Inc. Common Stock (TVTX) vs XP Inc. Class A Common Stock (XP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs XP Inc. Class A Common Stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while XP Inc. Class A Common Stock trades at $30.48 (market cap $15.93B). The key difference: XP Inc. Class A Common Stock is far larger — about 3.3× Travere Therapeutics Inc. Common Stock's market cap, and XP Inc. Class A Common Stock pays a 0.64% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and XP Inc. Class A Common Stock for 5 Days on average.
| TVTX | XP | |
|---|---|---|
Market Cap | $4.88B | $15.93B |
Volume | 1,668,577 | 10,243,374 |
Sector | Health | Financials |
52-Week High | $67.52 | $32.60 |
52-Week Low | $26.79 | $14.94 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $5.01B | $25.63B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XP Inc. trades at $31.38, down 3.74% today but remains near recent highs. The stock shows strong fundamental performance with 63.12% net income margin and 22.58% ROE, supported by consistent earnings beats in recent quarters. Technical indicators show mixed signals with bullish moving averages but overbought RSI readings. Analyst sentiment remains strongly positive with 80% buy ratings and price targets suggesting significant upside potential from current levels.
The outlook for XP remains favorable given its robust profitability metrics and growing revenue base, though investors should monitor competitive pressures and market volatility. The company's strong cash flow generation and institutional support provide stability, while technical overbought conditions suggest potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About XP Inc. Class A Common Stock
XP Inc. provides investment products and financial services in Brazil. Its platform includes brokerage, investment funds, fixed-income products, banking, insurance, and retirement solutions.
Read more on XP →
